ahlam1399
08-31-2015, 12:53 PM
Bayer moves heart drug to final tests after mid-stage success
(Reuters) - Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/496e72e3/sc/23/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=zcG_YQYr5V4:kzGd0JCfbr0:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zcG_YQYr5V4:kzGd0JCfbr0:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=zcG_YQYr5V4:kzGd0JCfbr0:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zcG_YQYr5V4:kzGd0JCfbr0:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=zcG_YQYr5V4:kzGd0JCfbr0:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/zcG_YQYr5V4
(Reuters) - Bayer will move a new heart failure drug into final-stage testing this year, boosting its ambitions in cardiovascular medicine, after the experimental medicine proved better than an older rival in a mid-stage trial.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/496e72e3/sc/23/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=zcG_YQYr5V4:kzGd0JCfbr0:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zcG_YQYr5V4:kzGd0JCfbr0:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=zcG_YQYr5V4:kzGd0JCfbr0:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=zcG_YQYr5V4:kzGd0JCfbr0:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=zcG_YQYr5V4:kzGd0JCfbr0:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/zcG_YQYr5V4